Biosortia, Inc.

Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover novel therapeutic agents. Through deep and direct access to this hidden chemistry, We create extensive data sets that are uniquely positioned to be leveraged by advanced computational and generative AI tools. These tools enable the prioritization of potential drug candidates by predicting their interaction with specific disease targets. By integrating AI with its vast repository of natural products, We can perform in silico testing to identify promising molecules, which can then be further optimized or derivatized to enhance their efficacy and safety profiles. Our approach accelerates the drug discovery process by moving seamlessly from computational predictions to real-world application. Our ability to obtain these prioritized molecules directly from their microbiome sources, or synthesize derivatives as needed, significantly shortens the timeline to preclinical testing and Investigational New Drug (IND) submissions. This capability not only streamlines the development of novel therapeutics but also provides a robust pipeline of next-generation products for the biotech industry. By combining its proprietary ISMM technology with cutting-edge AI, Biosortia is poised to transform the landscape of drug discovery. The company's platform offers biotech firms the ability to build pipeline opportunities rapidly. Duns #832707629 / Cage # 5TA50